RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
GlobalData on MSN1d
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
precisionmedicineonline1d
Regenxbio Treats First Patient in Pivotal Stage of Duchenne Muscular Dystrophy Gene Therapy Trial
The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
BioSpace1d
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Promising Initial Data and Favorable Regulatory Pathway Support Buy Rating for RegenXBio’s RGX-202 in DMD Treatment
Analyst Gena Wang from Barclays maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $50.00.Don't Miss ...
FierceBiotech1d
After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne ...
ENDPOINTS NEWS2d
Re­genxbio shares first da­ta show­ing Duchenne gene ther­a­py im­proves mus­cle func­tion
Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing ...